Co Diagnostics Stock Analysis

CODX Stock Analysis Notes

About 19.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.12. Some equities with similar Price to Book (P/B) outperform the market in the long run. Co Diagnostics recorded a loss per share of 29.4. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 2nd of January 2026. Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. For more info on Co Diagnostics please contact Dwight Egan at 801 438 1036 or go to https://co-dx.com.

Co Diagnostics Investment Alerts

CODX Largest EPS Surprises

View All Earnings Estimates

Co Diagnostics Environmental, Social, and Governance (ESG) Scores

CODX Stock Institutional Investors

Note, although Co Diagnostics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

CODX Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.92 M.

CODX Profitablity

Management Efficiency

Co Diagnostics has return on total asset (ROA) of (0.3792) % which means that it has lost $0.3792 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6212) %, meaning that it created substantial loss on money invested by shareholders. Co Diagnostics' management efficiency ratios could be used to measure how well Co Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.94 in 2026. Return On Capital Employed is likely to rise to -0.6 in 2026. At this time, Co Diagnostics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 38.3 M in 2026, whereas Total Assets are likely to drop slightly above 52.4 M in 2026.

Technical Drivers

As of the 13th of February 2026, Co Diagnostics owns the Variance of 122.99, market risk adjusted performance of (0.61), and Information Ratio of (0.15). Co Diagnostics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.

Co Diagnostics Price Movement Analysis

Co Diagnostics Insider Trading Activities

Co Diagnostics Outstanding Bonds

Co Diagnostics Predictive Daily Indicators

Co Diagnostics Forecast Models

Co Diagnostics' time-series forecasting models are one of many Co Diagnostics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Co Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Co Diagnostics Bond Ratings

Co Diagnostics financial ratings play a critical role in determining how much Co Diagnostics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Co Diagnostics' borrowing costs.

Co Diagnostics Debt to Cash Allocation

Co Diagnostics currently holds 2.15 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Co Diagnostics has a current ratio of 16.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Co Diagnostics' use of debt, we should always consider it together with its cash and equity.

Co Diagnostics Total Assets Over Time

Co Diagnostics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Co Diagnostics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Co Diagnostics Debt Ratio

3.67

It appears most of the Co Diagnostics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Co Diagnostics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Co Diagnostics, which in turn will lower the firm's financial flexibility.

Co Diagnostics Corporate Bonds Issued

CODX Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Co Diagnostics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CODX shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Co Diagnostics. By using and applying CODX Stock analysis, traders can create a robust methodology for identifying CODX entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CODX analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CODX analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Co Diagnostics stock analysis indicators help investors evaluate how Co Diagnostics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Co Diagnostics shares will generate the highest return on investment. By understating and applying Co Diagnostics stock analysis, traders can identify Co Diagnostics position entry and exit signals to maximize returns.

When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.